APP Pharmaceuticals Acquires Three Products from Nexus  
5/23/2012 10:57:14 AM

SCHAUMBURG, Ill.--(BUSINESS WIRE)--APP Pharmaceuticals, LLC, a Fresenius Kabi Company, today announced it has acquired three products from Nexus Pharmaceuticals, Inc. Under terms of the agreement APP takes complete ownership of the products and becomes the Abbreviated New Drug Application (ANDA) holder for Benztropine Mesylate Injection, Levetiracetam Injection and Tranexamic Acid Injection.